Immune booster added to cervix cancer treatment – study halted early
NCT ID NCT03144466
First seen May 09, 2026 · Last updated May 13, 2026 · Updated 1 time
Summary
This early-phase study aimed to see if adding the immunotherapy drug pembrolizumab to standard chemoradiation is safe for people with locally advanced cervix cancer. Only 1 person enrolled before the study was stopped. The goal was to find the safest dose and check for side effects, but no conclusions can be drawn due to early termination.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVIX CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Royal Marsden NHS Foundation Trust
London, SW3 6JJ, United Kingdom
Conditions
Explore the condition pages connected to this study.